Company News
Biocon EU Pertuzumab Biosimilar Approval Under New Pathway
Biocon received European Commission marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for HER2-positive breast cancer treatment.
This is the first biosimilar approved under EMA's new t